Business Segments · Total Assets
Pharmaceutical and Specialty Solutions — Total Assets
Cardinal Health Pharmaceutical and Specialty Solutions — Total Assets decreased by 5.5% to $41.03B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.8%, from $35.73B to $41.03B.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ2 2023
Last reportedQ1 2026
Rolls up toTotal Assets
How to read this metric
Growth in assets relative to revenue may indicate declining asset turnover or capital expansion.
Detailed definition
The total value of all assets, including inventory, accounts receivable, property, plant, equipment, and goodwill, speci...
Peer comparison
Standard measure of segment-level capital deployment in large healthcare organizations.
Metric ID:
cah_segment_pharmaceutical_and_specialty_solutions_total_assetsHistorical Data
10 periods
| Q2 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $27.62B | $30.50B | $29.15B | $29.22B | $32.13B | $35.73B | $37.31B | $38.68B | $43.41B | $41.03B |
| QoQ Change | — | +10.4% | -4.4% | +0.2% | +10.0% | +11.2% | +4.4% | +3.7% | +12.2% | -5.5% |
| YoY Change | — | — | +5.6% | — | — | +17.2% | +28.0% | +32.4% | +35.1% | +14.8% |
Range$27.62B – $43.41B
CAGR+19.2%
Avg YoY Growth+22.2%
Median YoY Growth+22.6%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Cardinal Health's pharmaceutical and specialty solutions — total assets?
- Cardinal Health (CAH) reported pharmaceutical and specialty solutions — total assets of $41.03B in Q1 2026.
- How has Cardinal Health's pharmaceutical and specialty solutions — total assets changed year-over-year?
- Cardinal Health's pharmaceutical and specialty solutions — total assets increased by 14.8% year-over-year, from $35.73B to $41.03B.
- What does pharmaceutical and specialty solutions — total assets mean?
- The total value of resources and assets dedicated to the pharmaceutical and specialty solutions segment.